Drugs / allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00006100 | Apr 2000 → ? | lymphoma | Milton S. Hershey Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00002956 | Nov 1996 → Feb 2002 | leukemia, lymphoma | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00005606 | Feb 2000 → Sep 2003 | leukemia, plasma cell neoplasm | Northwestern University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005606 ↗ |
| Modality | Cell therapy | “Autologous and allogeneic Epstein Barr virus (EBV) reactive lymphocytes are isolated from patients and siblings and tested in vitro for cytotoxic activity.” NCT00005606 ↗ |